london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Intravitreal bevacizumab in the management of chronic central serous chorio-retinopathy

Session Details

Session Title: Quick Fire Free Paper 5

Session Date/Time: Sunday 14/09/2014 | 11:00-13:00

Paper Time: 11:35

Venue: Boulevard B

First Author: : K.H.Madan INDIA

Co Author(s): :    S. Mittal              

Abstract Details

Purpose:

To present a case series of 12 patients of chronic Central Serous Chorio-retinopathy treated with intra-vitreal Bevacizumab.

Setting:

Interventional Case Series.

Methods:

Twelve consecutive patients of chronic Central Serous Chorio-retinopathy (CSR) were treated with intravitreal injection of 2.5 mg Bevacizumab at 4 week intervals for 3 months. Diagnosis of chronic Central Serous Chorio-retinopathy was made on the basis of duration of disease (more than 9 months). It was confirmed by Fundus Examination, Optical Coherence Tomography (OCT) and Fundus Fluorescein Angiography (FFA). Best Corrected Visual Acuity (BCVA), Fundus Examination, Optical Coherence Tomography (OCT) were performed at every 4 week intervals.

Results:

More than 2 lines of improvement in visual acuity was seen in 9 (75%) eyes. Complete resolution of sub retinal fluid was seen in 10 out of 12 eyes (83%).

Conclusions:

Intra-vitreal Bevacizumab can be a treatment option in patients of chronic Central Serous Chorio-retinopathy.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy